{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:11:20Z","timestamp":1790716280407,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00393-023-01355-0","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T13:05:11Z","timestamp":1685711111000},"page":"587-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunglobulin-A-Vaskulitis (IgAV)","Immunoglobulin A vasculitis (IgAV)"],"prefix":"10.1007","volume":"82","author":[{"given":"Katharina","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Eric","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Iking-Konert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"issue":"1","key":"1355_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"key":"1355_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","volume":"360","author":"JM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin\u00a0JM, Dolezalova\u00a0P, Cummins\u00a0C et al (2002) Incidence of Henoch-Sch\u00f6nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360:1197\u20131202","journal-title":"Lancet"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/annrheumdis-2018-214142","volume":"78","author":"A Tracy","year":"2019","unstructured":"Tracy\u00a0A, Subramanian\u00a0A, Adderley\u00a0NJ et al (2019) Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Sch\u00f6nlein purpura): a\u00a0retrospective cohort study using routinely collected primary care data. Ann Rheum Dis 78:261\u2013269","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1355_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1875-9572(09)60056-5","volume":"50","author":"SP Hung","year":"2009","unstructured":"Hung\u00a0SP, Yang\u00a0YH, Lin\u00a0YT et al (2009) Clinical manifestations and outcomes of Henoch-Sch\u00f6nlein purpura: comparison between adults and children. Pediatr Neonatol 50(4):162\u2013168","journal-title":"Pediatr Neonatol"},{"issue":"12","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke\u00a0MH, Ballering\u00a0AV, Jamin\u00a0A et al (2017) New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura). Autoimmun Rev 16(12):1246\u20131253","journal-title":"Autoimmun Rev"},{"issue":"14","key":"1355_CR6","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.3390\/ijms22147538","volume":"22","author":"H Sugino","year":"2021","unstructured":"Sugino\u00a0H, Sawada\u00a0Y, Nakamura\u00a0M (2021) IgA vasculitis: etiology, treatment, biomarkers and epigenetic changes. Int J Mol Sci 22(14):7538","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1355_CR7","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/rheumatology\/keab662","volume":"61","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen\u00a0C, Abitbol\u00a0V, El Karoui\u00a0K et al (2022) IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF\u2011\u03b1 blockers. Rheumatology 61(5):1957\u20131965","journal-title":"Rheumatology"},{"issue":"1","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"102707","DOI":"10.1016\/j.autrev.2020.102707","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen\u00a0C, Tisseyre\u00a0M, Garon-Czmil\u00a0J et al (2021) Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a\u00a0dual pharmacovigilance-based approach. Autoimmun Rev 20(1):102707","journal-title":"Autoimmun Rev"},{"issue":"5 Suppl","key":"1355_CR9","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaad.2005.10.011","volume":"55","author":"JM Zurada","year":"2006","unstructured":"Zurada\u00a0JM, Ward\u00a0KM, Grossman\u00a0ME (2006) Henoch-Sch\u00f6nlein purpura associated with malignancy in adults. J\u00a0Am Acad Dermatol 55(5 Suppl):S65\u2013S70","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1355_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2340\/00015555-1288","volume":"92","author":"JO Podjasek","year":"2012","unstructured":"Podjasek\u00a0JO, Wetter\u00a0DA, Pittelkow\u00a0MR et al (2012) Henoch-Sch\u00f6nlein purpura associated with solid-organ malignancies: three case reports and a\u00a0literature review. Acta Derm Venereol 92(4):388\u2013392","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1355_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/art.1780330809","volume":"33","author":"JA Mills","year":"1990","unstructured":"Mills\u00a0JA, Michel\u00a0BA, Bloch\u00a0DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Henoch-Sch\u00f6nlein purpura. Arthritis Rheum 33(8):1114\u20131121","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1355_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen\u00a0S, Pistorio\u00a0A, Iusan\u00a0SM et al (2010) Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69(5):798\u2013806","journal-title":"Ann Rheum Dis"},{"key":"1355_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-016-0959-4","volume":"18","author":"A Ho\u010devar","year":"2016","unstructured":"Ho\u010devar\u00a0A, Rotar\u00a0Z, Jur\u010di\u0107\u00a0V et\u00a0al (2016) IgA vasculitis in adults: the performance of the EULAR\/PRINTO\/PRES classification criteria in adults. Arthritis Res Ther 18:58","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1355_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11926-021-01013-x","volume":"23","author":"K Yaseen","year":"2021","unstructured":"Yaseen\u00a0K, Herlitz\u00a0LC, Villa-Forte\u00a0A (2021) IgA vasculitis in adults: a\u00a0rare yet challenging disease. Curr Rheumatol Rep 23(7):50","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"1355_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.ASN.0000013883.99976.22","volume":"13","author":"E Pillebout","year":"2002","unstructured":"Pillebout\u00a0E, Thervet\u00a0E, Hill\u00a0G, Alberti\u00a0C et al (2002) Henoch-Sch\u00f6nlein Purpura in adults: outcome and prognostic factors. J\u00a0Am Soc Nephrol 13(5):1271\u20131278","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3390\/jcm10112310","volume":"10","author":"E Pillebout","year":"2021","unstructured":"Pillebout\u00a0E (2021) IgA Vasculitis and IgA nephropathy: same disease? J\u00a0Clin Med 10(11):2310","journal-title":"J Clin Med"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13075-019-2089-2","volume":"21","author":"A Ho\u010devar","year":"2019","unstructured":"Ho\u010devar\u00a0A, Tom\u0161i\u010d\u00a0M, Jur\u010di\u0107\u00a0V et\u00a0al (2019) Predicting gastrointestinal and renal involvement in adult IgA vasculitis. Arthritis Res Ther 21:302","journal-title":"Arthritis Res Ther"},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00467-011-2070-z","volume":"27","author":"Q Lin","year":"2012","unstructured":"Lin\u00a0Q, Min\u00a0Y, Li\u00a0Y et al (2012) Henoch-Sch\u00f6nlein purpura with hypocomplementemia. Pediatr Nephrol 27:801\u2013806","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1093\/rheumatology\/keaa104","volume":"59","author":"A Audemard-Verger","year":"2020","unstructured":"Audemard-Verger\u00a0A, Pillebout\u00a0E, Amoura\u00a0Z et al (2020) Gastrointestinal involvement in adult IgA vasculitis (Henoch-Sch\u00f6nlein purpura): updated picture from a\u00a0French multicentre and retrospective series of 260\u00a0cases. Rheumatology 59(10):3050\u20133057","journal-title":"Rheumatology"},{"issue":"4S","key":"1355_CR20","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100(4S):S1\u2013S276","journal-title":"Kidney Int"},{"issue":"9","key":"1355_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","volume":"58","author":"S Ozen","year":"2019","unstructured":"Ozen\u00a0S, Marks\u00a0SD, Brogan\u00a0P et al (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology 58(9):1607\u20131616","journal-title":"Rheumatology"},{"issue":"1","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler\u00a0DC, Toto\u00a0RD, Stef\u00e1nsson\u00a0BV et al (2021) DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215\u2013224","journal-title":"Kidney Int"},{"issue":"15","key":"1355_CR23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et al (2020) DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"key":"1355_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","author":"WG Herrington","year":"2022","unstructured":"MPA-KIDNEY Collaborative Group, Herrington\u00a0WG, Staplin\u00a0N, Wanner\u00a0C et al (2022) Empagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.40339","volume":"70","author":"F Maritati","year":"2018","unstructured":"Maritati\u00a0F, Fenoglio\u00a0R, Pillebout\u00a0E et al (2018) Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Sch\u00f6nlein). Arthritis Rheumatol 70:109\u2013114","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1067\/mpd.2000.103448","volume":"136","author":"BJ Foster","year":"2000","unstructured":"Foster\u00a0BJ, Bernard\u00a0C, Drummond\u00a0KN et al (2000) Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a\u00a0clinical and histopathologic study. J\u00a0Pediatr 136(3):370\u2013375","journal-title":"J Pediatr"},{"issue":"9","key":"1355_CR27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1631\/jzus.B1400335","volume":"16","author":"F Han","year":"2015","unstructured":"Han\u00a0F, Chen\u00a0LL, Ren\u00a0PP et al (2015) Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Sch\u00f6nlein purpura nephritis: a\u00a0retrospective study. J\u00a0Zhejiang Univ Sci\u00a0B 16(9):772\u2013779","journal-title":"J Zhejiang Univ Sci B"},{"issue":"6","key":"1355_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","volume":"47","author":"R Coppo","year":"2006","unstructured":"Coppo\u00a0R, Andrulli\u00a0S, Amore\u00a0A et al (2006) Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults. Am J Kidney Dis 47(6):993\u20131003","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1355_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/qjmed\/hcl034","volume":"99","author":"S Shrestha","year":"2006","unstructured":"Shrestha\u00a0S, Sumingan\u00a0N, Tan\u00a0J et\u00a0al (2006) Henoch Sch\u00f6nlein purpura with nephritis in adults: adverse prognostic indicators in a\u00a0UK population. QJM 99(4):253\u2013265","journal-title":"QJM"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01355-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:02:47Z","timestamp":1694444567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01355-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"22 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Iking-Konert<\/b>: A.\u00a0Finanzielle Interessen: C.\u00a0Iking-Konert gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Mitarbeiter am UKE seit 2010, aktuell Wiss. Mitarbeiter; aktuell angestellt am Stadtspital Zurich seit dem 15.11.21 als Chefarzt der Abteilung f\u00fcr Rheumatologie. Mitgliedschaften: Schweizer Gesellschaft f\u00fcr Rheumatologie (SGR), Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Kommission Pharmakotherapie der DGRh; Kommission Covid19 der DGRh; Kommission \u201eKlug entscheiden\u201c der DGIM, Arbeitsgemeinschaft Kapillarmikroskopie der DGRh. <b>K.\u00a0Rose<\/b>: A.\u00a0Finanzielle Interessen: K.\u00a0Rose gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Abteilung f\u00fcr Rheumatologie, Stadtspital Z\u00fcrich | Mitgliedschaften: DGRh, DGIM. <b>J.-E.\u00a0Turner<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: LIMM Therapeutics, finanzielle Projektf\u00f6rderung.\u00a0\u2013 Novartis\u00a0\u2013 Reise\u2011\/\u00dcbernachtungskosten, Vortragshonorar; TADA Pharm\u00a0\u2013 Reise\u2011\/\u00dcbernachtungskosten, Vortragshonorar.\u00a0\u2013 FOMF: Vortrag; Nephrolive (Streamed Up GmbH): Vortrag; Vifor: Beraterhonorare; STADA GmbH: Beraterhonorare; Novartis: Beraterhonorare; Otsuka: Beraterhonorare.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen:  Angestellter Nephrologe, Universit\u00e4tsklinikum Hamburg-Eppendorf.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}